| __timestamp | Mesoblast Limited | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 55305000 | 7050000 |
| Thursday, January 1, 2015 | 77593000 | 8413000 |
| Friday, January 1, 2016 | 50013000 | 12038000 |
| Sunday, January 1, 2017 | 58914000 | 17900000 |
| Monday, January 1, 2018 | 65927000 | 15765000 |
| Tuesday, January 1, 2019 | 59815000 | 11140000 |
| Wednesday, January 1, 2020 | 56188000 | 11715000 |
| Friday, January 1, 2021 | 53012000 | 17344000 |
| Saturday, January 1, 2022 | 32815000 | 22829000 |
| Sunday, January 1, 2023 | 27189000 | 12665000 |
| Monday, January 1, 2024 | 25353000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Mesoblast Limited and MiMedx Group, Inc. have showcased contrasting R&D investment strategies. Mesoblast Limited, a leader in regenerative medicine, consistently outspent MiMedx Group, Inc., with its R&D expenses peaking in 2015 at nearly 78 million USD. However, by 2023, Mesoblast's R&D spending had decreased by approximately 65%, reflecting a strategic shift or financial constraints.
Conversely, MiMedx Group, Inc., known for its advanced wound care solutions, maintained a more conservative R&D budget, with a notable increase in 2022, reaching its highest at 23 million USD. This 224% rise from 2014 highlights MiMedx's growing commitment to innovation. As we look to 2024, the absence of data for MiMedx suggests potential changes in their R&D focus.
Merck & Co., Inc. or MiMedx Group, Inc.: Who Invests More in Innovation?
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs MiMedx Group, Inc.
Research and Development: Comparing Key Metrics for Summit Therapeutics Inc. and MiMedx Group, Inc.
Research and Development Investment: Dr. Reddy's Laboratories Limited vs Mesoblast Limited
Comparing Innovation Spending: Grifols, S.A. and Mesoblast Limited
R&D Insights: How ADMA Biologics, Inc. and MiMedx Group, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and MiMedx Group, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs Mesoblast Limited
Research and Development: Comparing Key Metrics for Catalyst Pharmaceuticals, Inc. and Mesoblast Limited
Cost of Revenue Trends: Mesoblast Limited vs MiMedx Group, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Mesoblast Limited and Evotec SE
Who Prioritizes Innovation? R&D Spending Compared for Amphastar Pharmaceuticals, Inc. and MiMedx Group, Inc.